^
BIOMARKER:

RET fusion

i
Other names: RET, Ret Proto-Oncogene, Proto-Oncogene Tyrosine-Protein Kinase Receptor Ret, Cadherin-Related Family Member 16, Rearranged During Transfection, RET Receptor Tyrosine Kinase, Cadherin Family Member 12, Proto-Oncogene C-Ret, CDHF12, CDHR16, PTC, Ret Proto-Oncogene (Multiple Endocrine Neoplasia And Medullary Thyroid Carcinoma 1, Hirschsprung Disease), Multiple Endocrine Neoplasia And Medullary Thyroid Carcinoma 1, Hirschsprung Disease 1, RET-ELE1, HSCR1, MEN2A, MEN2B, RET51, MTC1
Entrez ID:
20d
Clinical
|
RET (Ret Proto-Oncogene)
|
RET fusion
|
Retevmo (selpercatinib)
20d
Clinical
|
RET (Ret Proto-Oncogene) • NTRK3 (Neurotrophic tyrosine kinase, receptor, type 3)
|
NTRK3 fusion • RET fusion • RET positive
|
Retevmo (selpercatinib)
21d
Clinical
|
RET (Ret Proto-Oncogene)
|
RET fusion • RET positive
|
Gavreto (pralsetinib)
1m
Clinical
|
RET (Ret Proto-Oncogene) • NTRK3 (Neurotrophic tyrosine kinase, receptor, type 3)
|
NTRK3 fusion • RET fusion • RET positive
|
Retevmo (selpercatinib)
1m
Preclinical
|
RET (Ret Proto-Oncogene) • NTRK3 (Neurotrophic tyrosine kinase, receptor, type 3) • NTRK (Neurotrophic receptor tyrosine kinase)
|
NTRK3 fusion • RET fusion • NTRK fusion • RET positive
|
Retevmo (selpercatinib)
1m
Clinical
|
RET (Ret Proto-Oncogene)
|
RET fusion • RET positive
|
Gavreto (pralsetinib)
1m
Clinical
|
RET (Ret Proto-Oncogene) • NTRK3 (Neurotrophic tyrosine kinase, receptor, type 3)
|
NTRK3 fusion • RET fusion • RET positive
|
Retevmo (selpercatinib)
1m
Clinical
|
RET (Ret Proto-Oncogene) • NTRK3 (Neurotrophic tyrosine kinase, receptor, type 3)
|
NTRK3 fusion • RET fusion • RET positive
|
Retevmo (selpercatinib)
1m
Clinical
|
RET (Ret Proto-Oncogene) • NTRK3 (Neurotrophic tyrosine kinase, receptor, type 3)
|
NTRK3 fusion • RET fusion
1m
EGFR (Epidermal growth factor receptor) • BRAF (B-raf proto-oncogene) • RET (Ret Proto-Oncogene)
|
BRAF V600E • BRAF V600 • RET fusion
|
Tagrisso (osimertinib)
2ms
Clinical
|
RET (Ret Proto-Oncogene)
|
RET fusion • RET positive
|
Gavreto (pralsetinib)
2ms
Clinical
|
RET (Ret Proto-Oncogene)
|
RET fusion • RET positive
|
Gavreto (pralsetinib)
2ms
Clinical
|
RET (Ret Proto-Oncogene)
|
RET fusion • RET positive
|
Gavreto (pralsetinib)
2ms
Clinical
|
RET (Ret Proto-Oncogene) • NTRK3 (Neurotrophic tyrosine kinase, receptor, type 3)
|
NTRK3 fusion • RET fusion • RET positive
|
Retevmo (selpercatinib)
2ms
Clinical
|
RET (Ret Proto-Oncogene)
|
RET fusion • RET positive
|
Gavreto (pralsetinib)
2ms
RET (Ret Proto-Oncogene)
|
RET fusion
2ms
Clinical
|
RET (Ret Proto-Oncogene)
|
RET fusion
|
Retevmo (selpercatinib)
3ms
Clinical • Next-generation sequencing
|
KRAS (KRAS proto-oncogene GTPase) • RET (Ret Proto-Oncogene)
|
RET fusion • RET mutation
3ms
Clinical
|
RET (Ret Proto-Oncogene) • NTRK3 (Neurotrophic tyrosine kinase, receptor, type 3)
|
NTRK3 fusion • RET fusion • RET positive
|
Retevmo (selpercatinib)
4ms
RET (Ret Proto-Oncogene) • KIF5B (Kinesin Family Member 5B)
|
RET fusion • KIF5B-RET fusion
4ms
RET (Ret Proto-Oncogene)
|
RET fusion
5ms
RET (Ret Proto-Oncogene)
|
RET fusion
5ms
Clinical • FDA event
|
RET (Ret Proto-Oncogene)
|
RET fusion • RET positive
|
Gavreto (pralsetinib)
5ms
Clinical
|
RET (Ret Proto-Oncogene)
|
RET fusion
|
Retevmo (selpercatinib)
5ms
Clinical
|
RET (Ret Proto-Oncogene) • NTRK3 (Neurotrophic tyrosine kinase, receptor, type 3)
|
NTRK3 fusion • RET fusion • RET positive
|
Retevmo (selpercatinib)
5ms
Clinical
|
RET (Ret Proto-Oncogene) • NTRK3 (Neurotrophic tyrosine kinase, receptor, type 3) • NTRK (Neurotrophic receptor tyrosine kinase)
|
NTRK3 fusion • RET fusion • NTRK fusion • RET positive
|
Retevmo (selpercatinib)